Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have earned a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $20.40.

Several research firms recently weighed in on ARTV. Cantor Fitzgerald reduced their price objective on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, March 26th. Wedbush reiterated an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, April 8th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Franklin Resources Inc. bought a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $7,435,000. Geode Capital Management LLC boosted its position in Artiva Biotherapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after purchasing an additional 6,828 shares during the period. Northern Trust Corp increased its holdings in shares of Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after purchasing an additional 4,335 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Artiva Biotherapeutics by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after acquiring an additional 3,233 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Artiva Biotherapeutics by 250.7% during the fourth quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company’s stock worth $379,000 after acquiring an additional 26,893 shares during the period.

Artiva Biotherapeutics Stock Performance

ARTV opened at $2.20 on Friday. Artiva Biotherapeutics has a 1-year low of $1.78 and a 1-year high of $17.31. The firm has a 50-day moving average price of $3.24 and a two-hundred day moving average price of $6.93.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15). As a group, equities research analysts predict that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.